This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (19)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Genetics, Other  • Alert me on articles by topic

Susanne B. Haga, PhD; Wylie Burke, MD, PhD

JAMA. 2004;291:2869-2871.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Pharmacogenetics, the tailoring of drug treatment according to individual genotype, has been widely proclaimed as a first step toward personalized medicine. In this issue of THE JOURNAL, Chasman et al¹ report the association of 2 common polymorphisms in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene with reduced efficacy of pravastatin therapy. In a survey of 148 single nucleotide polymorphisms in 10 genes involved in lipid metabolism, carriers of 2 linked SNPs in the HMGCR gene showed significantly smaller reductions in levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol with treatment. Statins, the most potent and widely used cholesterol-lowering drugs, function as competitive inhibitors of HMGCR, the rate-limiting enzyme for cholesterol synthesis. This study is the first to demonstrate the impact of genetic variation in the HMGCR drug target for this popular class of drugs, justifying the need for further study to validate . . . [Full Text of this Article]

Author Affiliations: The Center for the Advancement of Genomics, Rockville, Md (Dr Haga); Department of Medical History and Ethics, University of Washington, Seattle (Dr Burke).

RELATED ARTICLE

Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction
Daniel I. Chasman, David Posada, Lakshman Subrahmanyan, Nancy R. Cook, Vincent P. Stanton, Jr, and Paul M Ridker
JAMA. 2004;291(23):2821-2827.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Intersection Of Biotechnology And Pharmacogenomics: Health Policy Implications
Phillips
Health Aff (Millwood) 2006;25:1271-1280.
ABSTRACT | FULL TEXT  

From genomics to drug targets.
Dahl and Sylte
J Psychopharmacol 2006;20:95-99.
ABSTRACT  

Randomised by (your) god: robust inference from an observational study design
Smith
J. Epidemiol. Community Health 2006;60:382-388.
FULL TEXT  

Genetic Variation in Response to Statin Therapy
Journal Watch Cardiology 2004;2004:1-1.
FULL TEXT